tiprankstipranks
The Fly

Solid Biosciences reports Q4 EPS ($1.00), consensus (78c)

Solid Biosciences reports Q4 EPS ($1.00), consensus (78c)

Solid had $148.9M in cash, cash equivalents, and available-for-sale securities as of December 31. Bo Cumbo, president and CEO of Solid, commented: “The diligent execution of our Duchenne and FA development programs over the last 18 months has transformed Solid and given us tremendous momentum into 2025 and beyond. The initial 90-day data from the first three participants in the Phase 1/2 INSPIRE DUCHENNE trial of our next-generation Duchenne muscular dystrophy (Duchenne) program, SGT-003, while early, have shown a reassuring safety experience and promising improvements in biomarkers of muscle integrity and health. We believe these early indicators support the potential of SGT-003 to be a best-in-class gene therapy candidate to treat Duchenne. We understand the excitement around these data in the Duchenne patient communities and we are committed to moving with purpose and urgency to bring SGT-003 through the clinic as quickly as possible.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com